Earnings Scheduled For February 22, 2023
Companies Reporting Before The Bell
• Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022.
Dada Nexus, Bilibili And Other Big Stocks Moving Lower On Monday
U.S. stocks traded lower, with the Nasdaq Composite dropping over 100 points on Monday. Here are some big stocks recording losses in today’s session.
SVB Leerink Maintains Outperform on Repligen, Lowers Price Target to $200
SVB Leerink analyst Puneet Souda maintains Repligen (NASDAQ:RGEN) with a Outperform and lowers the price target from $230 to $200.
Why Olaplex Shares Dipped Around 57%; Here Are 75 Biggest Movers From Yesterday
Gainers
Amprius Technologies, Inc. (NYSE: AMPX) jumped 77.3% to settle at $11.01 on Wednesday after the company announced it was awarded a $50 million cost-sharing grant from the U.S. Department of Energy's Office of Manufacturing and Energy Supply Chains.
Why United Airlines Shares Are Trading Higher? Here Are 43 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
SenesTech, Inc. (NASDAQ: SNES) shares jumped 102.6% to $0.47 after declining over 3% on Tuesday. SenesTech, during August, posted a Q2 loss of $0.21 per share.
Repligen Beefs Up Process Analytics Portfolio With DRS Daylight Solutions Pact
Repligen Corporation (NASDAQ:RGEN) entered into a strategic partnership and exclusive license agreement with DRS Daylight Solutions to expand the use of…
Golden Cross Appears Before Repligen Investors
If history is any guide, there may be good fortune ahead for shares of Repligen (NASDAQ:RGEN). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.
Catalent-Repligen Merger ‘Seems Unlikely,’ This Analyst Says
Yesterday, Catalent Inc (NYSE:CTLT) announced to acquire Metrics Contract Services for $475 million. Keybanc notes that the deal strengthens CTLT’s oral delivery…
Expert Ratings for Repligen
Analysts have provided the following ratings for Repligen (NASDAQ:RGEN) within the last quarter:
SVB Leerink Maintains Outperform on Repligen, Raises Price Target to $250
SVB Leerink analyst Puneet Souda maintains Repligen (NASDAQ:RGEN) with a Outperform and raises the price target from $220 to $250.